Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS)

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial randomized 10,061 patients with prior MI and persistently elevated hs-CRP to canakinumab — a monoclonal antibody targeting interleukin-1β (IL-1β) — at doses of 50, 150, or 300 mg every 3 months, versus placebo. LDL-C was not affected; this was a pure anti-inflammatory intervention.

Canakinumab at 150 mg significantly reduced major adverse cardiovascular events (CV death, MI, stroke) by 15% (HR 0.85, p=0.021), with corresponding reductions in hs-CRP. The 50 mg dose did not reach significance; the 300 mg dose did not provide additional benefit over 150 mg. Infection rates, including fatal infections, were higher with canakinumab — a predictable consequence of IL-1β pathway blockade. LDL-C did not change, confirming that the cardiovascular benefit was attributable to inflammation reduction, not lipid effects.

CANTOS was a definitive proof-of-concept trial for the inflammatory hypothesis of atherothrombosis. Prior to CANTOS, the strongest evidence was epidemiological — CRP predicts events and statins reduce CRP and events. CANTOS decoupled inflammation reduction from lipid lowering and showed that targeting inflammation independently reduces cardiovascular events. The subsequent colchicine trials (COLCOT, LoDoCo2) extended this finding to a cheaper, safer agent.

We rate the evidence strong. A landmark RCT proving that anti-inflammatory therapy independent of lipid lowering reduces cardiovascular events — establishing the inflammatory pathway as a causally validated therapeutic target in secondary prevention.